Summary & Overview
HCPCS S3721: Prostate Cancer Antigen 3 (PCA3) Testing
HCPCS Level II code S3721 denotes prostate cancer antigen 3 (PCA3) testing, a molecular laboratory assay used to assess prostate cancer–related risk by measuring PCA3 RNA levels in urine. Nationally, the code matters as molecular diagnostics increasingly inform prostate cancer evaluation, influencing diagnostic pathways and utilization of specialty laboratory services. Payers and providers use this code to classify and process claims for PCA3 assays performed in outpatient or clinical laboratory settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage and billing context, common service settings, and the clinical rationale for PCA3 testing. The publication presents benchmarks for utilization and reimbursement where available, highlights relevant policy updates affecting molecular diagnostic billing, and summarizes clinical context regarding when PCA3 testing is used in prostate cancer assessment. Data not available in the input are noted where applicable. The content is intended for a national audience of payers, health system billing staff, and clinical laboratory leadership seeking clear, policy-oriented information about HCPCS Level II code S3721 and its role in prostate cancer diagnostics.
Billing Code Overview
HCPCS Level II code S3721 represents Prostate cancer antigen 3 (PCA3) testing. The code describes a molecular diagnostic test that measures PCA3, a prostate cancer–associated noncoding RNA, used to aid clinical assessment related to prostate cancer risk and management.
Service Type: Laboratory — molecular diagnostic test
Typical Site of Service: Outpatient laboratory or clinical laboratory facility
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a man aged 50–75 with elevated or rising prostate-specific antigen (PSA) levels, prior negative or indeterminate prostate biopsy(s), or other clinical concern for prostate cancer despite normal imaging. The clinician (urologist or primary care physician) orders S3721 (Prostate cancer antigen 3 (PCA3) testing) as a urine-based molecular diagnostic to improve risk stratification for prostate cancer prior to repeat biopsy.
The clinical workflow: the patient provides a first-catch urine sample collected after a standard digital rectal exam (DRE) to increase prostatic cell shedding. The specimen is handled per laboratory instructions and sent to a certified molecular diagnostics lab. The laboratory performs PCA3 testing and reports a PCA3 score. The ordering clinician reviews the PCA3 score alongside PSA, DRE findings, prior biopsy pathology, imaging (if available), and patient preferences to determine the need for repeat biopsy, surveillance, or further imaging such as multiparametric MRI. Typical sites of service include outpatient clinic, urology office, or outpatient laboratory collection center.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional interpretation component if applicable for lab-performed molecular tests with separate physician interpretation. |